Bristol Myers Squibb's arlo-cel meets phase II goal in relapsed multiple myeloma
Bristol Myers Squibb reports that its phase II QUINTESSENTIAL trial of arlocabtagene autoleucel met the main goal in adults with relapsed and refractory multiple myeloma.